CAJ | 학술논문

我国《专利法》除第5条用以预防科学技术危害外，还应当增设生物技术风险评价制度以控制生物技术风险。在专利申请的实质性审查阶段增设生物技术风险评价制度，在广泛的公众参与下，结合生物技术发明人的技术风险自我评价，由特定的生物技术风险评价机构对生物技术发明的生态风险、社会风险以及人体健康风险进行风险评价，最终由专利审查机构针对风险评价的结论对高风险生物技术不授予专利授权，从而阻滞高风险生物技术的产业化发展，实现专利法控制生物技术风险的基本功能。
아국《전리법》제제5조용이예방과학기술위해외，환응당증설생물기술풍험평개제도이공제생물기술풍험。재전리신청적실질성심사계단증설생물기술풍험평개제도，재엄범적공음삼여하，결합생물기술발명인적기술풍험자아평개，유특정적생물기술풍험평개궤구대생물기술발명적생태풍험、사회풍험이급인체건강풍험진행풍험평개，최종유전리심사궤구침대풍험평개적결론대고풍험생물기술불수여전리수권，종이조체고풍험생물기술적산업화발전，실현전리법공제생물기술풍험적기본공능。
In addition to art. 5 of China Patent Law which regulates science and technological hazards, it is necessary to establish the risk assessment system of biotechnological technology in patent examining procedure, in order to control the risk of biotechnological technology. It is advised that the patent examining division should decide whether a biotechnological patent can be granted or not after considering the risk assessment results of health risk assessment, environmental risk assessment and social risk assessment made by particular risk assessment agencies, in order to prevent the industrial development of the high risk biotechnological technology and realize the basic function of patent law to control the biotechnological technology risk.